Le Lézard
Classified in: Health, Science and technology, Covid-19 virus
Subjects: Event, Annual Meeting

Top Life Sciences Leaders Assemble for "Illuminate," the 2023 DIA Global Annual Meeting


DIA, the premier professional global community for healthcare product development, will host its 2023 Global Annual Meeting in Boston, June 25-29. In keeping with this year's theme, "Illuminate," the event underscores the importance of convening global sponsors, CROs, regulators, academics, and patients face-to-face for honest and open collaboration that illuminates the path to the future of healthcare and ignites critical change in drug, device, and diagnostic development.

"For more than 50 years, DIA has played a key role in the global drug development industry ecosystem but there's so much more we must do," said Marwan Fathallah, DIA's recently named President and Global Chief Executive. "The innovative spirit of the 2023 Global Annual Meeting brings together the world's top scientific minds, industry leaders, regulators, and public policy influencers in one place to share meaningful, revolutionary insights on the challenges that lie ahead. As we emerge from the COVID-19 pandemic, we see the dawning of a new day in clinical development. We have opportunities to transform the industry as we know it for the benefit of patients everywhere."

This year, the meeting's opening keynote plenary and panel discussion will be led by Dr. Junaid Bajwa, the Chief Medical Scientist at Microsoft Research, and a practicing physician in the UK's National Health Service. The discussion will focus on how diversity, innovation, and artificial intelligence (AI) are transforming the life sciences industry.

On track to be one of DIA's largest events, with more than 5,000 attendees and 500+ speakers, the Global Annual Meeting is the preeminent industry-neutral forum for the entire international healthcare value chain ranging from policy and regulation to research and development, marketing, and access. Meeting participants are afforded unique access to top executives, scientific minds, regulators, academics, and patient advocates from Africa, Asia, Europe, North America, and South America to collaboratively explore and problem-solve some of the biggest issues facing the industry ? from diversity, equity, and inclusion and decentralized clinical trials (DCT) to AI and advances in oncology.

DIA's 2023 Global Annual Meeting includes over 170 sessions spanning across 13 educational tracks. Highly anticipated sessions at the event include:

Learn more about DIA's 2023 Global Annual Meeting by exploring the searchable event program, and by registering for the event here.

About DIA

DIA (founded as the Drug Information Association) is a global association that mobilizes life science professionals from across all areas of expertise to engage with patients, peers, and thought leaders in a neutral environment on the issues of today and the possibilities for tomorrow. As a member-driven, volunteer organization, professionals from 80 countries have affected healthcare outcomes by engaging with DIA through an unparalleled network, educational offerings, and professional development opportunities. DIA is based in Washington, DC (US) with regional offices representing the Americas (Horsham, PA, US); Europe, the Middle East, and Africa, (Basel, Switzerland); and Asia (Beijing and Shanghai, China; Mumbai, India; and Tokyo, Japan).

For live updates, search social media with #DIA2023, and connect with DIA on Twitter, LinkedIn, Facebook, and Instagram.


These press releases may also interest you

at 03:05
Owkin, the first end-to-end AI-biotech unicorn that provides best-in-class AI-driven precision drug discovery, development and diagnostics, has announced its expansion into the DACH region (Germany, Austria and Switzerland) following partnerships...

at 03:05
We are excited to share our latest development status. We are pleased to announce that the enrollment of patients in the Phase III clinical trial of DFP-14323 in combination with Afatinib (20 mg/day) versus Afatinib (40 mg/day) alone in stage...

at 02:50
Two hospitals in Belgium are successfully live with the public cloud service from international medical imaging IT and cybersecurity company Sectra (STOCKHOLM: SECT-B). As the first to use Sectra One Cloud in the Benelux countries, the two hospitals...

at 02:03
Barrington James, a global leader in Life Science Recruitment, proudly announces the acquisition of S3 Science Recruitment, a firm renowned for its expertise in drug discovery, medical research, and the broader field of life sciences. Terms of the...

at 02:00
July 3, 2024 Amsterdam, the Netherlands ? Royal Philips , a global leader in health technology, today announced the appointment of Ms Ling Liu as the Chief Region Leader of Philips Greater China, effective immediately. Ms Liu is now a member of...

at 01:39
Hansa Biopharma, "Hansa" , will publish its interim report for January-June 2024 on July 18, 2024. Interested parties may join the Company's quarterly conference call on the same date at 14:00 CEST/8:00 AM EST. The event will be hosted by Søren...



News published on and distributed by: